Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) have earned an average rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month target price among […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) has been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price […]